Literature DB >> 31445730

Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification.

Xiu Huang1, Lexin Xia1, Fen Lan1, Yang W Shao2, Wen Li1, Yang Xia3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31445730     DOI： 10.1016/j.jtho.2019.04.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  6 in total

1.  Effect of Comprehensive Nursing Based on Cognitive Behavior on Psychological Function of Glioma Patients.

Authors:  Yu-Hong Zhao; Yan Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-10       Impact factor: 2.570

2.  Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.

Authors:  Giulio Metro; Sara Baglivo; Guido Bellezza; Martina Mandarano; Alessio Gili; Giovanni Marchetti; Marco Toraldo; Carmen Molica; Maria Sole Reda; Francesca Romana Tofanetti; Annamaria Siggillino; Enrico Prosperi; Antonella Giglietti; Bruna Di Girolamo; Miriam Garaffa; Francesca Marasciulo; Vincenzo Minotti; Marco Gunnellini; Annalisa Guida; Monica Sassi; Angelo Sidoni; Fausto Roila; Vienna Ludovini
Journal:  Genes (Basel)       Date:  2021-04-30       Impact factor: 4.096

3.  Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.

Authors:  Wei Wang; Meihong Wu; Minglu Liu; Zhengqing Yan; Guoqiang Wang; Dongliang Mao; Mei Wang
Journal:  J Immunother Cancer       Date:  2020-06-23       Impact factor: 13.751

4.  Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.

Authors:  Jie Li; Junrong Yan; Ran Cao; Guanjun Du; Guofang Zhao
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

Review 5.  "Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Authors:  Guoqing Zhang; Beibei Yan; Yanan Guo; Hang Yang; Jindong Li
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

6.  The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.

Authors:  Ting Zhang; Xue Yang; Jing Zhao; Lixia Xia; Qiyuan Wang; Rui Jin; Lingxiao Zhou; Bin Zhang; Jun Zhao; Huijie Li; Wen Li; Yang Xia
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.